OBJECTIVE: Ferumoxytol, an iron oxide nanoparticle that targets phagocytic cells, can be used in magnetic resonance imaging of malignant brain tumors and can be administered as a bolus, allowing dynamic imaging. Our objectives were to determine the optimum time of delayed contrast enhancement of ferumoxytol, and to compare ferumoxytol and gadolinium contrast agents for magnetic resonance angiography and perfusion. METHODS: Twelve patients with malignant brain tumors underwent serial magnetic resonance imaging multiple times up to 72 hours after ferumoxytol injection at both 1.5 and 3-T. The enhancement time course was determined for ferumoxytol and compared with a baseline gadolinium scan. Perfusion, time-of-flight and dynamic magnetic resonance angiography and T1-weighted scans were compared for the two agents. RESULTS: The lesions were detectable at all field strengths, even with an intraoperative 0.15-T magnet. Maximal ferumoxytol enhancement intensity was at 24 to 28 hours after administration, and the enhancing volume subsequently expanded with time into a non-gadolinium-enhancing, high T2-weighted signal region of tumor-infiltrated brain. Dynamic studies were assessed with both agents, indicating early vascular leak with gadolinium but not with ferumoxytol. CONCLUSION: Our most important finding was that gadolinium leaks out of blood vessels early after injection, whereas ferumoxytol stays intravascular in the "early" phase, thereby increasing the accuracy of tumor perfusion assessment. As a magnetic resonance imaging contrast agent, ferumoxytol visualizes brain tumors at all field strengths evaluated, with delayed enhancement peaking at 24 to 28 hours after administration.
OBJECTIVE:Ferumoxytol, an iron oxide nanoparticle that targets phagocytic cells, can be used in magnetic resonance imaging of malignant brain tumors and can be administered as a bolus, allowing dynamic imaging. Our objectives were to determine the optimum time of delayed contrast enhancement of ferumoxytol, and to compare ferumoxytol and gadolinium contrast agents for magnetic resonance angiography and perfusion. METHODS: Twelve patients with malignant brain tumors underwent serial magnetic resonance imaging multiple times up to 72 hours after ferumoxytol injection at both 1.5 and 3-T. The enhancement time course was determined for ferumoxytol and compared with a baseline gadolinium scan. Perfusion, time-of-flight and dynamic magnetic resonance angiography and T1-weighted scans were compared for the two agents. RESULTS: The lesions were detectable at all field strengths, even with an intraoperative 0.15-T magnet. Maximal ferumoxytol enhancement intensity was at 24 to 28 hours after administration, and the enhancing volume subsequently expanded with time into a non-gadolinium-enhancing, high T2-weighted signal region of tumor-infiltrated brain. Dynamic studies were assessed with both agents, indicating early vascular leak with gadolinium but not with ferumoxytol. CONCLUSION: Our most important finding was that gadolinium leaks out of blood vessels early after injection, whereas ferumoxytol stays intravascular in the "early" phase, thereby increasing the accuracy of tumor perfusion assessment. As a magnetic resonance imaging contrast agent, ferumoxytolvisualizes brain tumors at all field strengths evaluated, with delayed enhancement peaking at 24 to 28 hours after administration.
Authors: Costas G Hadjipanayis; Revaz Machaidze; Milota Kaluzova; Liya Wang; Albert J Schuette; Hongwei Chen; Xinying Wu; Hui Mao Journal: Cancer Res Date: 2010-07-20 Impact factor: 12.701
Authors: Sadhana Jackson; Nicole M Anders; Antonella Mangraviti; Teresia M Wanjiku; Eric W Sankey; Ann Liu; Henry Brem; Betty Tyler; Michelle A Rudek; Stuart A Grossman Journal: J Neurooncol Date: 2015-12-01 Impact factor: 4.130
Authors: Csanad G Varallyay; Eric Nesbit; Andrea Horvath; Peter Varallyay; Rongwei Fu; Seymur Gahramanov; Leslie L Muldoon; Xin Li; William D Rooney; Edward A Neuwelt Journal: J Magn Reson Imaging Date: 2018-01-04 Impact factor: 4.813
Authors: Edit Dósa; Suchita Tuladhar; Leslie L Muldoon; Bronwyn E Hamilton; William D Rooney; Edward A Neuwelt Journal: Stroke Date: 2011-04-14 Impact factor: 7.914
Authors: Gerda B Toth; Csanad G Varallyay; Andrea Horvath; Mustafa R Bashir; Peter L Choyke; Heike E Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S Vasanawala; Prakash Ambady; Ramon Barajas; Justin S Cetas; Jeremy Ciporen; Thomas J DeLoughery; Nancy D Doolittle; Rongwei Fu; John Grinstead; Alexander R Guimaraes; Bronwyn E Hamilton; Xin Li; Heather L McConnell; Leslie L Muldoon; Gary Nesbit; Joao P Netto; David Petterson; William D Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A Neuwelt Journal: Kidney Int Date: 2017-04-20 Impact factor: 10.612
Authors: Saeid Zanganeh; Gregor Hutter; Ryan Spitler; Olga Lenkov; Morteza Mahmoudi; Aubie Shaw; Jukka Sakari Pajarinen; Hossein Nejadnik; Stuart Goodman; Michael Moseley; Lisa Marie Coussens; Heike Elisabeth Daldrup-Link Journal: Nat Nanotechnol Date: 2016-09-26 Impact factor: 39.213
Authors: L Henry Bryant; Saejeong J Kim; Matthew Hobson; Blerta Milo; Zsofia I Kovacs; Neekita Jikaria; Bobbi K Lewis; Maria A Aronova; Alioscka A Sousa; Guofeng Zhang; Richard D Leapman; Joseph A Frank Journal: Nanomedicine Date: 2016-08-09 Impact factor: 5.307
Authors: Csanad G Varallyay; Leslie L Muldoon; Seymur Gahramanov; Yingjen J Wu; James A Goodman; Xin Li; Martin M Pike; Edward A Neuwelt Journal: J Cereb Blood Flow Metab Date: 2009-01-14 Impact factor: 6.200